{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:56:15Z","timestamp":1781718975403,"version":"3.54.5"},"reference-count":38,"publisher":"Impact Journals, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,1,31]]},"DOI":"10.18632\/oncotarget.13315","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T03:25:00Z","timestamp":1478921100000},"page":"8910-8920","source":"Crossref","is-referenced-by-count":110,"title":["Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials"],"prefix":"10.18632","volume":"8","author":[{"given":"Ricardo","family":"Costa","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedito A.","family":"Carneiro","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Agulnik","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred W.","family":"Rademaker","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"},{"name":"Northwestern University Department of Preventive Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin G.","family":"Pai","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria M.","family":"Villaflor","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cristofanilli","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Sosman","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Giles","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,11,11]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1001\/jamaoncol.2015.3934","article-title":"Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration","volume":"2","author":"Pazdur","year":"2016","journal-title":"JAMA Oncol"},{"key":"2","first-page":"180","article-title":"Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Gurney","year":"2015","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Neyns","year":"2015","journal-title":"N Engl J Med"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Herbst, Baas, Kim, Felip, Perez-Gracia, Han, Molina, Kim, Arvis, Ahn, Majem, Fidler, de Castro, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7.","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Postow. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015; pp. 76\u201383. https:\/\/doi.org\/10.14694\/EdBook_AM.2015.35.76.","DOI":"10.14694\/EdBook_AM.2015.35.76"},{"key":"7","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of Immunotherapy for the Practitioner","volume":"33","author":"Disis","year":"2015","journal-title":"J Clin Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/jjco\/hyv199","article-title":"Nivolumab-induced organizing pneumonia in a melanoma patient","volume":"46","author":"Okuyama","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jtho.2015.10.004","article-title":"Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma","volume":"11","author":"Takahashi","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Wolchok","year":"2015","journal-title":"Ann Oncol"},{"key":"11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Wagstaff","year":"2015","journal-title":"N Engl J Med"},{"key":"12","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Arrieta","year":"2015","journal-title":"N Engl J Med"},{"key":"13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Gainor","year":"2015","journal-title":"N Engl J Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Lebbe","year":"2015","journal-title":"N Engl J Med"},{"key":"15","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"O\u2019Day","year":"2015","journal-title":"Lancet Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Lorigan","year":"2015","journal-title":"Lancet Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2217\/imt.15.87","article-title":"Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"7","author":"Fouad","year":"2015","journal-title":"Immunotherapy"},{"key":"18","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.2217\/fon.15.118","article-title":"Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis","volume":"11","author":"Fouad","year":"2015","journal-title":"Future Oncol"},{"key":"19","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer","volume":"33","author":"Leming","year":"2015","journal-title":"J Clin Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Antonia","year":"2012","journal-title":"N Engl J Med"},{"key":"21","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Felip","year":"2015","journal-title":"N Engl J Med"},{"key":"22","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial","volume":"33","author":"Lambert","year":"2015","journal-title":"J Clin Oncol"},{"key":"23","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Zaheer","year":"2015","journal-title":"N Engl J Med"},{"key":"24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ligon","year":"2015","journal-title":"N Engl J Med"},{"key":"25","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Zarour","year":"2014","journal-title":"Lancet"},{"key":"26","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1634\/theoncologist.2011-0163","article-title":"Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs","volume":"16","author":"Tabernero","year":"2011","journal-title":"Oncologist"},{"key":"27","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1093\/annonc\/mdt288","article-title":"Clinical biomarkers of response in advanced renal cell carcinoma","volume":"24","author":"Schmidinger","year":"2013","journal-title":"Ann Oncol"},{"key":"28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Pectasides","year":"2006","journal-title":"N Engl J Med"},{"key":"29","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Levy","year":"2005","journal-title":"J Clin Oncol"},{"key":"30","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes","volume":"22","author":"Weber","year":"2016","journal-title":"Clin Cancer Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1034\/j.1600-0749.2003.00023.x","article-title":"Evidence for an autoimmune pathogenesis of vitiligo","volume":"16","author":"Naeyaert","year":"2003","journal-title":"Pigment Cell Res"},{"key":"32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000079481","article-title":"Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments","volume":"66","author":"Shimizu","year":"2004","journal-title":"Oncology"},{"key":"33","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/JTO.0b013e318161225e","article-title":"Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901","volume":"3","author":"Cancer Leukemia Group","year":"2008","journal-title":"J Thorac Oncol"},{"key":"34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Yardley","year":"2012","journal-title":"N Engl J Med"},{"key":"35","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement","volume":"313","author":"Group","year":"2015","journal-title":"JAMA"},{"key":"36","volume-title":"Introduction to meta-analysis","author":"Rothstein","year":"2009"},{"key":"37","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Mazumdar","year":"1994","journal-title":"Biometrics"},{"key":"38","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Minder","year":"1997","journal-title":"BMJ"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T16:43:00Z","timestamp":1594831380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,11]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,1,31]]}},"alternative-id":["13315","27852042"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13315","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,11]]}}}